Jul 17, 2025 7:00 am EDT Castle Biosciences Honored with Multiple Top Workplaces Awards Recognizing the Company’s Strong Culture
Jul 14, 2025 7:00 am EDT Castle Biosciences to Release Second Quarter 2025 Financial Results and Host Conference Call on Monday, Aug. 4, 2025
Jun 19, 2025 7:00 am EDT Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jun 16, 2025 4:30 pm EDT Castle Biosciences Enters Collaboration and License Agreement with SciBase to Develop Diagnostic Tests for Dermatologic Diseases
Jun 11, 2025 7:00 am EDT Castle Biosciences’ Chief Executive Officer Derek Maetzold to Participate in Panel Discussion During the 2025 BIO International Convention
Jun 4, 2025 7:00 am EDT Castle Biosciences’ Founder, President and CEO Derek Maetzold Honored with Prestigious Lifetime Achievement Award by The American Business Awards®
May 29, 2025 4:30 pm EDT New Data at ASCO 2025 Affirms DecisionDx®-Melanoma's Ability to Improve Upon Staging-Based Risk Stratification and Predict Survival Outcomes
May 21, 2025 7:00 am EDT Castle Biosciences to Present at the 2025 Jefferies Global Healthcare Conference
May 9, 2025 7:00 am EDT Real-World Study Confirms Long-Term Performance of DecisionDx®-UM for Metastatic Risk Stratification in Uveal Melanoma and Utility of PRAME Biomarker for Refining Risk When Considered with the DecisionDx-UM Class Result
